Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from IGM

IGM ETF: Expand Tech Exposure With Top AI Leaders

The iShares Expanded Tech Sector ETF offers concentrated exposure to the leaders of the AI revolution through its unique, expanded-sector methodology.

Dozens Of Migrants Deported From US Arrive In Guatemala

Dozens Of Migrants Deported From US Arrive In Guatemala

Deported migrants from the US receive support in Guatemala. Efforts made to coordinate with Mexico on managing migration.

Capitalize on the AI Revolution With These 3 ETFs

Capitalize on the AI Revolution With These 3 ETFs

With many companies vying to dominate the AI space, it is difficult to assess which individual firms are best: AI ETFs help to maximize broad exposure.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

3 Tech ETFs for the AI and Cloud Computing Boom

In today’s digital world, Tech ETFs provide strong growth potential, diversification, and lower risk, and help capitalize on the AI and cloud computing boom. Hence, investors should consider top tech ETFs like iShares Expanded Tech Sector (IGM), Fidelity MSCI Information Technology Index (FTEC), and Vanguard Information Technology Index Fund (VGT).…

3 Exciting Tech ETFs to Consider Buying Now

As the tech industry is poised for remarkable growth, thanks to the tide of innovations and rapid digitization, it could be wise to invest in quality tech ETFs First Trust NASDAQ-100-Technology Sector Index Fund (QTEC), iShares Expanded Tech Sector ETF (IGM), and Vanguard Communication Services Index Fund (VOX). Read on.

RBC Capital Slashes IGM Financial Price Target By 11%

RBC Capital analyst Geoffrey Kwan lowered the price target for IGM Financial Inc. (TSX:IGM) (OTC:IGIFF) to C$47 from C$53 while maintaining the Sector Perform rating on the shares. Kwan notes the reduced target reflects lower financial forecasts given the significant decline in equity markets since the last report. Kwan believes IGM is delivering the best…

Why Did Truist Lower IGM Biosciences' Price Target?

Truist has lowered the price target on IGM Biosciences Inc (NASDAQ:IGMS) to $74 from $80. The analyst Asthika Goonewardene says that the lower price target reflects the Company's Q4 results, deal financials, and increased cost to IGM Biosciences in its Sanofi SA (NASDAQ:SNY) collaboration deal. Related: IGM Biosciences Shares Surge After Oncology / Immunology Pact With Sanofi.…

inkl

Read news from The Economist, FT, and more,
with one subscription

The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict

The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict

Here's a roundup of top developments in the biotech space over the last 24 hours.

IGM Biosciences Shares Surge After Oncology/Immunology Pact With Sanofi

IGM Biosciences Shares Surge After Oncology/Immunology Pact With Sanofi

Sanofi SA (NASDAQ: SNY) and IGM Biosciences Inc (NASDAQ: IGMS) have signed an exclusive worldwide collaboration agreement for IgM antibodies agonists against

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia

Here's a roundup of top developments in the biotech space over the last 24 hours:

1

Organisations

Food and Drug Administration

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

369,857 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play